Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

References 62

1. 1.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
2. 2.
   Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England · 2021

   No notice
3. 3.

   Volz E, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv. 2021;2020.2012.2030.20249034.

   Not in our library10.1101/2020.12.30.20249034

4. 4.

   Korber B, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182:812-827.

   Not in our library10.1016/j.cell.2020.06.043

5. 5.

   Yurkovetskiy L, et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell. 2020;183:739-751.

   Not in our library10.1016/j.cell.2020.09.032

6. 6.

   Martinot M, et al. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. 2020.

   Not in our library10.1093/cid/ciaa1474

7. 7.

   Kemp S, et al. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv. 2020;2020.2012.2005.20241927.

   Not in our library10.1101/2020.12.05.20241927

8. 8.
   Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity · 2021

   No notice
9. 9.

   Baden LR, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020.

   Not in our library10.1056/nejmoa2035389

10. 10.

    Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-2615.

    Not in our library10.1056/nejmoa2034577

11. 11.
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021

    Corrected
12. 12.

    Mulligan MJ, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589-593.

    Not in our library10.1038/s41586-020-2639-4

13. 13.

    Corbett KS, et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. bioRxiv. 2020;2020.2006.2011.145920.

    Not in our library10.1038/s41586-020-2622-0

14. 14.

    Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467-478.

    Not in our library10.1016/s0140-6736(20)31604-4

15. 15.
    Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 · 2021

    No notice
16. 16.

    Tegally H, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020;2020.2012.2021.20248640.

    Not in our library10.1101/2020.12.21.20248640

17. 17.

    Faria NR, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. 2021.

    Not in our library

18. 18.

    Jackson LA, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383:1920-1931.

    Not in our library10.1056/nejmoa2022483

19. 19.

    Walsh EE, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine. 2020;383:2439-2450.

    Not in our library10.1056/nejmoa2027906

20. 20.
    Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses · 2020

    No notice
21. 21.
    Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020

    No notice
22. 22.

    Wang PL, Iketani S, Luo Y, Guo Y, Ho D. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioXriv. 2021.

    Not in our library

23. 23.

    Public Health England statement on Variant of Concern and new Variant Under Investigation. 2021.

    Not in our library

24. 24.

    McCallum M, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv. 2021.

    Not in our library10.1016/j.cell.2021.03.028

25. 25.
    Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity · 2021

    No notice
26. 26.

    Greaney AJ, et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. Cell host & microbe. 2021.

    Not in our library10.1016/j.chom.2021.02.003

27. 27.
    SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma · 2021

    No notice
28. 28.

    Walls AC, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281-292.

    Not in our library10.1016/j.cell.2020.02.058

29. 29.

    Guan Y, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276-278.

    Not in our library10.1126/science.1087139

30. 30.

    Li W, et al. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J Virol. 2004;78:11429-11433.

    Not in our library10.1128/jvi.78.20.11429-11433.2004

31. 31.

    Li W, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. The EMBO journal. 2005;24:1634-1643.

    Not in our library10.1038/sj.emboj.7600640

32. 32.
    Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding · 2020

    No notice
33. 33.

    Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021.

    Not in our library10.1038/s41586-021-03324-6

34. 34.

    Wibmer CK, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021.

    Not in our library10.1038/s41591-021-01285-x

35. 35.

    Verschoor CP, et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PloS one. 2015;10:e0131531.

    Not in our library10.1371/journal.pone.0131531

36. 36.

    Kulkarni PS, Hurwitz JL, Simoes EAF, Piedra PA. Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field. Viral Immunol. 2018;31:195-203.

    Not in our library10.1089/vim.2017.0147

37. 37.

    Goddard NL, Cooke MC, Gupta RK, Nguyen-Van-Tam JS. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiol Infect. 2007;135:159-162.

    Not in our library10.1017/s0950268806006601

38. 38.

    Mercado NB, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586:583-588.

    Not in our library10.1038/s41586-020-2607-z

39. 39.

    McMahan K, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020.

    Not in our library10.1038/s41586-020-03041-6

40. 40.

    Rathnasinghe R, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv. 2021;2021.2001.2019.21249592.

    Not in our library10.1101/2021.01.19.21249592

Cited by papers we hold 35

• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
  No notice
• Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events · 2022
  No notice
• Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity · 2022
  No notice
• Predicting the mutational drivers of future SARS-CoV-2 variants of concern · 2022
  No notice
• FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines · 2022
  No notice
• Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals · 2021
  No notice
• CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 · 2021
  Not checked
• Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants · 2021
  No notice
• Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants · 2021
  No notice
• BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel · 2021
  Not checked
• Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 · 2021
  No notice
• Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine · 2021
  No notice
• SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern · 2021
  No notice
• SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion · 2021
  No notice
• Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy · 2021
  No notice
• Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland · 2021
  No notice
• COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies · 2021
  No notice

and 15 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.